Greenleaf Trust Trims Position in IQVIA Holdings Inc. $IQV

Greenleaf Trust lessened its stake in IQVIA Holdings Inc. (NYSE:IQV) by 32.6% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 1,899 shares of the medical research company’s stock after selling 920 shares during the period. Greenleaf Trust’s holdings in IQVIA were worth $299,000 as of its most recent SEC filing.

Other institutional investors also recently added to or reduced their stakes in the company. Clal Insurance Enterprises Holdings Ltd increased its stake in IQVIA by 436.7% in the 1st quarter. Clal Insurance Enterprises Holdings Ltd now owns 161 shares of the medical research company’s stock worth $28,000 after buying an additional 131 shares during the period. Golden State Wealth Management LLC increased its stake in IQVIA by 295.5% in the 1st quarter. Golden State Wealth Management LLC now owns 174 shares of the medical research company’s stock worth $31,000 after buying an additional 130 shares during the period. AllSquare Wealth Management LLC purchased a new position in IQVIA during the 1st quarter valued at about $33,000. Larson Financial Group LLC increased its position in IQVIA by 109.9% during the 1st quarter. Larson Financial Group LLC now owns 275 shares of the medical research company’s stock valued at $48,000 after purchasing an additional 144 shares during the period. Finally, Bruce G. Allen Investments LLC increased its position in IQVIA by 178.4% during the 1st quarter. Bruce G. Allen Investments LLC now owns 323 shares of the medical research company’s stock valued at $57,000 after purchasing an additional 207 shares during the period. Hedge funds and other institutional investors own 89.62% of the company’s stock.

IQVIA Trading Up 1.2%

Shares of IQV stock opened at $206.84 on Friday. The company’s 50-day moving average price is $187.90 and its 200-day moving average price is $167.56. IQVIA Holdings Inc. has a twelve month low of $134.65 and a twelve month high of $237.34. The company has a current ratio of 0.84, a quick ratio of 0.84 and a debt-to-equity ratio of 2.45. The stock has a market cap of $35.16 billion, a price-to-earnings ratio of 29.93, a PEG ratio of 2.27 and a beta of 1.32.

IQVIA (NYSE:IQV) last posted its earnings results on Tuesday, July 22nd. The medical research company reported $2.81 EPS for the quarter, beating analysts’ consensus estimates of $2.77 by $0.04. IQVIA had a net margin of 7.88% and a return on equity of 30.05%. The company had revenue of $4.02 billion for the quarter, compared to analysts’ expectations of $3.96 billion. During the same quarter in the prior year, the company posted $2.64 earnings per share. IQVIA’s revenue for the quarter was up 5.3% compared to the same quarter last year. IQVIA has set its FY 2025 guidance at 11.750-12.050 EPS. As a group, equities analysts predict that IQVIA Holdings Inc. will post 10.84 earnings per share for the current year.

Insider Transactions at IQVIA

In related news, insider Keriann Cherofsky sold 549 shares of the company’s stock in a transaction that occurred on Wednesday, July 23rd. The shares were sold at an average price of $191.53, for a total transaction of $105,149.97. Following the sale, the insider directly owned 2,910 shares in the company, valued at approximately $557,352.30. This represents a 15.87% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Eric Sherbet sold 5,800 shares of the company’s stock in a transaction that occurred on Wednesday, July 23rd. The stock was sold at an average price of $190.05, for a total transaction of $1,102,290.00. Following the sale, the insider owned 27,178 shares in the company, valued at $5,165,178.90. The trade was a 17.59% decrease in their ownership of the stock. The disclosure for this sale can be found here. 1.60% of the stock is owned by corporate insiders.

Analyst Ratings Changes

A number of research analysts have commented on IQV shares. Weiss Ratings reissued a “hold (c)” rating on shares of IQVIA in a research report on Saturday, September 27th. Mizuho raised their target price on shares of IQVIA from $190.00 to $225.00 and gave the company an “outperform” rating in a research report on Friday, July 25th. Evercore ISI raised their price target on shares of IQVIA from $170.00 to $180.00 and gave the company an “outperform” rating in a report on Wednesday, July 9th. Cowen restated a “buy” rating on shares of IQVIA in a report on Wednesday, July 23rd. Finally, Truist Financial raised their price target on shares of IQVIA from $209.00 to $235.00 and gave the company a “buy” rating in a report on Wednesday, July 23rd. Eighteen research analysts have rated the stock with a Buy rating and seven have issued a Hold rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $230.32.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.